Looks like David Suhy focusing on a bolton strategy is the right move for CAR-T
"Would fit into GILD's stated strategy: With the company less focused on additional
transformational deals at the moment and recently applying greater emphasis on bolstering
their new cell therapy platform through, as management has noted, potential interest and bolton’s
such as cell switching or gene-editing, we believe that Cell Design Labs fits well into GILD’s
approach."
BLT Price at posting:
20.5¢ Sentiment: Hold Disclosure: Held
